Moleculin Biotech (MBRX) closed at $8.70 on November 6, 2026, down 0.3% from the previous close, on volume of 14,020 shares (30-day average 399,038).
Data as of November 6, 2026.
Moleculin Biotech Reports Positive Annamycin Trial Interim Results
TipRanks (Wed, 4-Nov 5:05 PM ET)
Globe Newswire (Wed, 4-Nov 11:00 AM ET)
Globe Newswire (Fri, 30-Oct 8:40 AM ET)
Market Chameleon (Wed, 21-Oct 7:22 AM ET)
Market Chameleon (Tue, 20-Oct 7:02 AM ET)
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Globe Newswire (Tue, 20-Oct 8:12 AM ET)
Moleculin Announces Reverse Stock Split
Globe Newswire (Fri, 16-Oct 9:20 AM ET)
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Globe Newswire (Wed, 7-Oct 8:45 AM ET)
Globe Newswire (Tue, 29-Sep 8:45 AM ET)
Globe Newswire (Mon, 28-Sep 7:00 AM ET)
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Moleculin Biotech trades on the NASDAQ stock market under the symbol MBRX.
As of November 6, 2026, MBRX stock price declined to $8.70 with 14,020 million shares trading.
MBRX has a beta of -2.05, meaning it tends to be less sensitive to market movements. MBRX has a correlation of 0.01 to the broad based SPY ETF.
MBRX has a market cap of $8.87 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, MBRX traded as high as $7,874.96 and as low as $3.23.
The top ETF exchange traded funds that MBRX belongs to (by Net Assets): VXF.
MBRX has underperformed the market in the last year with a return of -96.2%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MBRX shares. However, MBRX has outperformed the market in the last 3 month and 2 week periods, returning +13.0% and +33.8%, while SPY returned -4.1% and -3.2%, respectively. This indicates MBRX has been having a stronger performance recently.
MBRX support price is $7.71 and resistance is $9.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBRX shares will trade within this expected range on the day.
